Morgan Stanley Reiterates Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $340
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has reiterated an Equal-Weight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raised the price target from $305 to $340.
June 30, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has reiterated an Equal-Weight rating on Vertex Pharmaceuticals and raised the price target from $305 to $340.
The reiteration of an Equal-Weight rating indicates that Morgan Stanley believes Vertex Pharmaceuticals is fairly valued at its current price. However, the increase in the price target from $305 to $340 suggests that they see potential for the stock's price to rise in the future. This could have a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100